Your Messages Inbox
Your Article Summary
See Latest ArticlesMerck Receives Positive CHMP Opinion for JANUVIAand JANUMET as Add-On to Insulin in the European Union
Merck & Co., 09/28/09
Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for JANUVIA tablets and JANUMET tablets recommending their use as add–on to insulin for the treatment of type 2 diabetes. If adopted by the European Commission, sitagliptin will be the only diabetes treatment in the DPP–4 inhibitor class to have an indication for use as add–on to insulin in the European Union.
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 10/30/09
Gyrus PlasmaKinetic bipolar coagulation device for liver resection
Australian and New Zealand Journal of Surgery, 11/13/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Article Search
Sponsor